Trials / Completed
CompletedNCT04711187
Study of AT-527 in Healthy Subjects (R07496998)
A Phase I Study Assessing the Safety and Pharmacokinetics of Multiple Doses of AT-527 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- Atea Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT-527 Formulation 1 | AT-527 Formulation 1 (R07496998) |
| OTHER | Placebo Comparator | Placebo Comparator |
| DRUG | AT-527 Formulation 2 | AT-527 Formulation 2 (R07496998) |
Timeline
- Start date
- 2020-11-02
- Primary completion
- 2021-09-15
- Completion
- 2021-09-15
- First posted
- 2021-01-15
- Last updated
- 2022-02-25
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04711187. Inclusion in this directory is not an endorsement.